Amyloidosis is a heterogeneous disorder resulting from the deposition of toxic insoluble beta-sheet fibrillar protein aggregates. Amyloidosis can be acquired or hereditary. The disease can be localized or systemic. Amyloid can accumulate in the liver, spleen, kidney, heart, nerves, and blood vessels, causing different clinical syndromes. The variation in presentation and rarity of amyloidosis makes it a challenging diagnosis to and one third of cases are not diagnosed up till until a year after presentation. Ultrastructural examination and chemical analysis reveal the complex nature of amyloid. It emerges that on the basis of morphology and physical characteristics, all forms of amyloid are similar in appearance, but they are chemically heterogeneous. Based on analysis, amyloid is composed of 2 main types of complex proteins: Fibril proteins comprise about 95% of amyloid and non-fibrillar components which include P-component predominantly and there are several other different proteins which together constitute the remaining 5% of amyloid. Although not common, amyloidosis is a serious disease that results in significant mortality and morbidity. The most challenging issue is significant delay in diagnosis, sometimes up to several years. Early suspicion and thorough investigation are critical to making a timely diagnosis and referral for treatment.

Keywords: Amyloidosis; Plasma; Kidney; Heart

References

1. Kyle RA. “Amyloidosis: a convoluted story”. British Journal of Haematology 114 (2001): 529.
2. Iadanza MG., et al. “A new era for understanding amyloid structures and disease”. Nature Reviews Molecular Cell Biology 19 (2018): 755.
3. Benson MD., et al. “Amyloid nomenclature 2018: recommendations by the International Society of Amyloidosis (ISA) nomenclature committee”. Amyloid 25 (2018): 215.
4. Real de Asúa., et al. “Systemic AA amyloidosis: epidemiology, diagnosis, and management”. Clinical Epidemiology 6 (2014): 369-377.
5. Spice JD., et al. “Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification ISA 2016 nomenclature guidelines”. (2016).
6. Juneja R and Pati HP. “Approach to the Diagnosis of Amyloidosis”. Indian Journal of Hematology and Blood Transfusion 2 (2020): 246-253.
7. Gertz MA. “Immunoglobulin light chain amyloidosis: 2016 update on diagnosis, prognosis, and treatment”. American Journal of Hematology9 (2016): 947-956.
8. Kebbel A and Röcken C. “Immunohistochemical classification of amyloid in surgical pathology revisited”. The American Journal of Surgical Pathology 6 (2006): 673-683.
9. Mollee P., et al. “How to diagnose amyloidosis”. Internal Medical Journal1 (2014): 7-17.

Citation

Citation: Gurpreet Kaur., et al. “Amyloidosis - An Overview”.Acta Scientific Cancer Biology 8.3 (2024): 09-15.

Copyright

Copyright: © 2024 Gurpreet Kaur., et al. “Study of p16INK4a Immunostaining as Specific Biomarker in the diagnosis of Cervical Intraepithelial Neoplasia and This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.